| Not Yet Recruiting | Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Strati NCT07414667 | Central Hospital, Nancy, France | — |
| Not Yet Recruiting | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases NCT07212322 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Not Yet Recruiting | Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Ca NCT07290946 | Christian von Buchwald | Phase 2 |
| Recruiting | A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (45 NCT07118241 | Lubris Bio Pty Ltd | Phase 2 |
| Not Yet Recruiting | Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome NCT07192666 | Guangdong ProCapZoom Biosciences Co., Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | MSCohi-O Lenses for Ocular Involvement in Sjögren's Syndrome NCT07185139 | Guangdong ProCapZoom Biosciences Co., Ltd. | EARLY_Phase 1 |
| Recruiting | A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) NCT06747949 | Amgen | Phase 3 |
| Terminated | A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome NCT06544642 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome NCT05946941 | Bristol-Myers Squibb | Phase 3 |
| Completed | The Effect of Chewing Gum, Exercises of the Tongue, Lip, Jaw on Salivation, Xerostomia, Dysphagia in Sjögren's NCT05680064 | Saglik Bilimleri Universitesi | N/A |
| Completed | Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome NCT05605665 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Unknown | Objective Measurement With TCM Pattern for AIDDES NCT04747288 | Taipei Veterans General Hospital, Taiwan | — |
| Completed | Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (p NCT04572841 | Sanofi | Phase 2 |
| Completed | HRR as a Novel Biomarker in Sjögren's Syndrome NCT05633524 | Tianjin Eye Hospital | — |
| Completed | A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome NCT04129164 | Amgen | Phase 2 |
| Unknown | Impact of Korean Red Ginseng on Fatigue in Patients With Rheumatic Disease NCT03983408 | Hanyang University | N/A |
| Withdrawn | Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome NCT03937271 | Taipei Veterans General Hospital, Taiwan | — |
| Unknown | DNA Exome Sequencing TCM for Sjögren's Syndrome NCT03935373 | Taipei Veterans General Hospital, Taiwan | — |
| Completed | SS-INQ Information Needs Questionnaire in Sjögren's Syndrome NCT04798911 | University College, London | — |
| Unknown | Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction NCT03434106 | LanZhou University | N/A |
| Unknown | Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ? NCT03060005 | Tung Wah Hospital | N/A |
| Terminated | Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary NCT02843659 | Bristol-Myers Squibb | Phase 2 |
| Unknown | Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome. NCT02849093 | Bedford Hospital NHS Trust | — |
| Completed | A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome. NCT04111341 | Chung Shan Medical University | Phase 2 |
| Completed | A Study of LY3090106 in Participants With Sjögren's Syndrome (SS) NCT02614716 | Eli Lilly and Company | Phase 1 |
| Completed | A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome NCT02422407 | Biogen | — |
| Completed | Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome NCT02067910 | University Medical Center Groningen | Phase 3 |
| Unknown | Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome NCT02112019 | Derk Jan Jager | N/A |
| Unknown | Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's S NCT02855658 | China Medical University Hospital | Phase 2 |
| Unknown | Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome NCT02110446 | Chang Gung Memorial Hospital | Phase 2 |
| Completed | e-Mobile Tablet for People With Chronic Conditions NCT02833311 | Case Western Reserve University | N/A |
| Completed | Salivary Biomarkers for Sjögren's Syndrome Detection NCT01807689 | University of California, Los Angeles | — |
| Terminated | Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects NCT01316770 | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 |
| Unknown | Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation NCT01174329 | Universidad Autonoma de Nuevo Leon | Phase 2 / Phase 3 |
| Unknown | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases NCT01151644 | University of Sao Paulo | Phase 4 |
| Completed | Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome NCT01160666 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Low Dose Cyclosporin A in Primary Sjögren Syndrome NCT01693393 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome NCT01008982 | University of Udine | Phase 2 |
| Completed | Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients NCT00873496 | Ege University | — |
| Available | Managed Access Programs for VAY736, Ianalumab NCT07244289 | Novartis Pharmaceuticals | — |